October 2020 in “Revista médica sinergía/Revista médica sinergia” Alopecia areata is a complex condition causing hair loss, linked to genetics and immune system issues, and may be related to other autoimmune diseases; treatments vary in effectiveness.
Different scalp and hair disorders are more common in certain ethnic groups, with the most common being androgenetic alopecia, which is treated with medications like minoxidil and finasteride.
October 2024 in “Clinical Cosmetic and Investigational Dermatology” Brevilin-A is a safe and effective treatment for mild to moderate alopecia areata in children.
11 citations
,
September 2024 in “Journal of the European Academy of Dermatology and Venereology” Hair regrows faster in alopecia areata than skin re-pigments in vitiligo due to differences in stem cells and treatment effects.
18 citations
,
February 2023 in “eLife” ILC1-like cells can independently cause alopecia areata.
January 2026 in “Experimental Dermatology” Skin-resident memory T cells may contribute to chronic alopecia areata and baricitinib could be a potential treatment.
April 2024 in “International journal of molecular sciences” Alopecia areata and vitiligo share immune system dysfunction but differ in specific immune responses and affected areas.
ILC1-like cells can independently cause alopecia areata by affecting hair follicles.
November 2022 in “Journal of Investigative Dermatology” Statins may help treat alopecia areata by reducing harmful immune interactions.
37 citations
,
December 2021 in “Cells” Alopecia areata severity and treatment response are linked to specific cytokine levels.
1 citations
,
August 2023 in “Biomolecules” Certain immune-related proteins are higher in people with alopecia and their healthy relatives, hinting at a genetic link.
19 citations
,
August 2017 in “American journal of clinical dermatology” Hepatitis B virus exposure may be linked to increased risk of alopecia areata.
1 citations
,
September 2025 in “Frontiers in Immunology” Alopecia areata involves complex immune dysregulation, mainly driven by Th1 activity, suggesting broader treatment strategies.
1 citations
,
May 2022 in “Frontiers in Pharmacology” Astilbin can potentially calm overactive immune responses, like in Type 1 Diabetes, by suppressing certain cell activities and reducing inflammation.
Certain immune markers and vitamin levels could help diagnose alopecia areata.
April 2025 in “BMC Immunology” Targeting SIRT1 with antisense oligonucleotides could be a promising treatment for hair loss.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” The study developed a mouse model for Alopecia Areata that responds to treatment, useful for future research.
July 2022 in “Journal of Investigative Dermatology” IL-15 helps maintain hair growth and protects the immune status of hair follicles.
46 citations
,
October 2018 in “JCI insight” CD8+ T cells are involved in alopecia areata and may cause disease relapse.
26 citations
,
October 2016 in “American journal of clinical dermatology” New treatments like JAK inhibitors show promise for reversing alopecia areata.
25 citations
,
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” Targeted cytokine treatments may help with alopecia areata, but more research is needed.
6 citations
,
December 2013 in “Journal of Investigative Dermatology Symposium Proceedings” Alopecia areata involves complex immune and genetic factors, with potential treatment targets identified, but more research is needed.
1 citations
,
October 2020 in “Journal of Investigative Dermatology Symposium Proceedings” The summit concluded that new treatments like Jak inhibitors show promise for Alopecia Areata and personalized approaches are needed.
January 2019 in “Springer eBooks” Combination therapies might work better for some vitiligo patients, but results vary.
91 citations
,
May 2023 in “Journal of Cutaneous Medicine and Surgery” Alopecia Areata affects 2% globally, with treatments like essential oils, garlic, and JAK inhibitors showing promise, but more research is needed.
14 citations
,
July 2021 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” Interleukin levels are higher in alopecia areata patients but don't predict disease severity or duration.
8 citations
,
July 2024 in “European journal of medical research” Alopecia areata after COVID-19 vaccination is rare but important to recognize for timely treatment.
5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
2 citations
,
April 2025 in “Biologics” Dupilumab and ustekinumab are promising treatments for alopecia areata, showing significant hair regrowth.
1 citations
,
March 2023 in “Clinical, Cosmetic and Investigational Dermatology” Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.